-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On September 28, Innovent announced that with UNION therapeutics, UNION’s main drug candidate for the treatment of inflammatory skin diseases, orismilast, a potential best-in-class PDE4 inhibitor in clinical phase II, has reached an agreement in China (including mainland China).
According to the terms of the agreement, Cinda Bio will obtain the exclusive rights to research, development and commercialization of orismilast in China
Orismilast is a potent and highly selective next-generation PDE4 inhibitor with a wide range of anti-inflammatory properties
Based on orsimilast, UNION has two product candidates in clinical phase II development
There are approximately 50 million patients with atopic dermatitis and 6 million patients with psoriasis in China, and the incidence is showing a gradual increase with changes in life>